Bio-Medical Applications Of Alabama Inc. is a medicare approved dialysis facility center in Brewton, Alabama and it has 14 dialysis stations. It is located in Escambia county at 1205 Belleville Ave., Brewton, AL, 36426. You can reach out to the office of Bio-Medical Applications Of Alabama Inc. at (251) 867-3650. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Bio-Medical Applications Of Alabama Inc. has the following ownership type - Profit. It was first certified by medicare in March, 1994. The medicare id for this facility is 012549 and it accepts patients under medicare ESRD program.
| Name | Bio-Medical Applications Of Alabama Inc. |
|---|---|
| Location | 1205 Belleville Ave., Brewton, Alabama |
| No. of Dialysis Stations | 14 |
| Medicare ID | 012549 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 1205 Belleville Ave., Brewton, Alabama, 36426 | |
| (251) 867-3650 | |
News Archive
For the study, PET scans were performed on the brains of 13 elderly men and women with mild cognitive impairment (MCI) and 14 elderly people without memory problems.
Two patients with melanoma that had spread to the liver survived for at least 8.5 and 12 years after resection of the hepatic tumor and treatment with patient-specific immunotherapeutic vaccines.
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases..
Physicians at the Jefferson Hospital for Neuroscience (JHN), the region's only dedicated hospital for neuroscience, are tackling a particularly aggressive brain cancer that even surgery, chemotherapy and radiation often fail to treat with a promising new immunotherapy to attack a patient's tumor with their own cancer cells.
› Verified 4 days ago
| NPI Number | 1710325410 |
| Organization Name | Fresenius Medical Care Brewton |
| Doing Business As | Bio-medical Applications Of Alabama, Inc. |
| Address | 1203 Belleville Ave Brewton, Alabama, 36426 |
| Phone Number | (251) 867-3650 |
News Archive
For the study, PET scans were performed on the brains of 13 elderly men and women with mild cognitive impairment (MCI) and 14 elderly people without memory problems.
Two patients with melanoma that had spread to the liver survived for at least 8.5 and 12 years after resection of the hepatic tumor and treatment with patient-specific immunotherapeutic vaccines.
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases..
Physicians at the Jefferson Hospital for Neuroscience (JHN), the region's only dedicated hospital for neuroscience, are tackling a particularly aggressive brain cancer that even surgery, chemotherapy and radiation often fail to treat with a promising new immunotherapy to attack a patient's tumor with their own cancer cells.
› Verified 4 days ago
| NPI Number | 1932181278 |
| Doing Business As | Dialysis Affiliates Of South Alabama |
| Address | 1205 Belleville Ave Brewton, Alabama, 36426 |
| Phone Number | (251) 867-3650 |
News Archive
For the study, PET scans were performed on the brains of 13 elderly men and women with mild cognitive impairment (MCI) and 14 elderly people without memory problems.
Two patients with melanoma that had spread to the liver survived for at least 8.5 and 12 years after resection of the hepatic tumor and treatment with patient-specific immunotherapeutic vaccines.
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases..
Physicians at the Jefferson Hospital for Neuroscience (JHN), the region's only dedicated hospital for neuroscience, are tackling a particularly aggressive brain cancer that even surgery, chemotherapy and radiation often fail to treat with a promising new immunotherapy to attack a patient's tumor with their own cancer cells.
› Verified 4 days ago
| Dialysis patients with Hemoglobin data | 21 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 14 |
News Archive
For the study, PET scans were performed on the brains of 13 elderly men and women with mild cognitive impairment (MCI) and 14 elderly people without memory problems.
Two patients with melanoma that had spread to the liver survived for at least 8.5 and 12 years after resection of the hepatic tumor and treatment with patient-specific immunotherapeutic vaccines.
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases..
Physicians at the Jefferson Hospital for Neuroscience (JHN), the region's only dedicated hospital for neuroscience, are tackling a particularly aggressive brain cancer that even surgery, chemotherapy and radiation often fail to treat with a promising new immunotherapy to attack a patient's tumor with their own cancer cells.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 33 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 304 |
| Percentage of adult patients getting regular hemodialysis at the center | 99 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
For the study, PET scans were performed on the brains of 13 elderly men and women with mild cognitive impairment (MCI) and 14 elderly people without memory problems.
Two patients with melanoma that had spread to the liver survived for at least 8.5 and 12 years after resection of the hepatic tumor and treatment with patient-specific immunotherapeutic vaccines.
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases..
Physicians at the Jefferson Hospital for Neuroscience (JHN), the region's only dedicated hospital for neuroscience, are tackling a particularly aggressive brain cancer that even surgery, chemotherapy and radiation often fail to treat with a promising new immunotherapy to attack a patient's tumor with their own cancer cells.
› Verified 4 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Bio-Medical Applications Of Alabama Inc. with elevated calcium levels.
| Patients with hypercalcemia | 34 |
| Hypercalcemia patient months | 311 |
| Patients with Serumphosphor | 34 |
| Patients with Serumphosphor less than 3.5 mg/dL | 14 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 29 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 28 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 23 |
| Patients with Serumphosphor greater than 7 mg/dL | 7 |
News Archive
For the study, PET scans were performed on the brains of 13 elderly men and women with mild cognitive impairment (MCI) and 14 elderly people without memory problems.
Two patients with melanoma that had spread to the liver survived for at least 8.5 and 12 years after resection of the hepatic tumor and treatment with patient-specific immunotherapeutic vaccines.
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases..
Physicians at the Jefferson Hospital for Neuroscience (JHN), the region's only dedicated hospital for neuroscience, are tackling a particularly aggressive brain cancer that even surgery, chemotherapy and radiation often fail to treat with a promising new immunotherapy to attack a patient's tumor with their own cancer cells.
› Verified 4 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 29 |
| Patient months included in arterial venous fistula and catheter summaries | 245 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 56 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 26 |
News Archive
For the study, PET scans were performed on the brains of 13 elderly men and women with mild cognitive impairment (MCI) and 14 elderly people without memory problems.
Two patients with melanoma that had spread to the liver survived for at least 8.5 and 12 years after resection of the hepatic tumor and treatment with patient-specific immunotherapeutic vaccines.
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases..
Physicians at the Jefferson Hospital for Neuroscience (JHN), the region's only dedicated hospital for neuroscience, are tackling a particularly aggressive brain cancer that even surgery, chemotherapy and radiation often fail to treat with a promising new immunotherapy to attack a patient's tumor with their own cancer cells.
› Verified 4 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 30 |
| Hospitalization Rate in facility | 107.7 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 244.6 |
| Hospitalization Rate: Lower Confidence Limit | 50.6 |
News Archive
For the study, PET scans were performed on the brains of 13 elderly men and women with mild cognitive impairment (MCI) and 14 elderly people without memory problems.
Two patients with melanoma that had spread to the liver survived for at least 8.5 and 12 years after resection of the hepatic tumor and treatment with patient-specific immunotherapeutic vaccines.
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases..
Physicians at the Jefferson Hospital for Neuroscience (JHN), the region's only dedicated hospital for neuroscience, are tackling a particularly aggressive brain cancer that even surgery, chemotherapy and radiation often fail to treat with a promising new immunotherapy to attack a patient's tumor with their own cancer cells.
› Verified 4 days ago
The rate of readmission show you whether patients who were being treated regularly at Bio-Medical Applications Of Alabama Inc. were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 31.5 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 52.5 |
| Readmission Rate: Lower Confidence Limit | 16 |
News Archive
For the study, PET scans were performed on the brains of 13 elderly men and women with mild cognitive impairment (MCI) and 14 elderly people without memory problems.
Two patients with melanoma that had spread to the liver survived for at least 8.5 and 12 years after resection of the hepatic tumor and treatment with patient-specific immunotherapeutic vaccines.
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases..
Physicians at the Jefferson Hospital for Neuroscience (JHN), the region's only dedicated hospital for neuroscience, are tackling a particularly aggressive brain cancer that even surgery, chemotherapy and radiation often fail to treat with a promising new immunotherapy to attack a patient's tumor with their own cancer cells.
› Verified 4 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Bio-Medical Applications Of Alabama Inc. get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.91 (As Expected) |
| SIR: Upper Confidence Limit | 3.97 |
| SIR: Lower Confidence Limit | .77 |
News Archive
For the study, PET scans were performed on the brains of 13 elderly men and women with mild cognitive impairment (MCI) and 14 elderly people without memory problems.
Two patients with melanoma that had spread to the liver survived for at least 8.5 and 12 years after resection of the hepatic tumor and treatment with patient-specific immunotherapeutic vaccines.
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases..
Physicians at the Jefferson Hospital for Neuroscience (JHN), the region's only dedicated hospital for neuroscience, are tackling a particularly aggressive brain cancer that even surgery, chemotherapy and radiation often fail to treat with a promising new immunotherapy to attack a patient's tumor with their own cancer cells.
› Verified 4 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Bio-Medical Applications Of Alabama Inc.'s rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 29 |
| Transfusion Rate in facility | 22.9 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 111.1 |
| Transfusion Rate: Lower Confidence Limit | 5.7 |
News Archive
For the study, PET scans were performed on the brains of 13 elderly men and women with mild cognitive impairment (MCI) and 14 elderly people without memory problems.
Two patients with melanoma that had spread to the liver survived for at least 8.5 and 12 years after resection of the hepatic tumor and treatment with patient-specific immunotherapeutic vaccines.
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases..
Physicians at the Jefferson Hospital for Neuroscience (JHN), the region's only dedicated hospital for neuroscience, are tackling a particularly aggressive brain cancer that even surgery, chemotherapy and radiation often fail to treat with a promising new immunotherapy to attack a patient's tumor with their own cancer cells.
› Verified 4 days ago
The rate of mortality show you whether patients who were being treated regularly at Bio-Medical Applications Of Alabama Inc. lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 139 |
| Mortality Rate in facility | 11.2 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 17.9 |
| Mortality Rate: Lower Confidence Limit | 6.5 |
News Archive
For the study, PET scans were performed on the brains of 13 elderly men and women with mild cognitive impairment (MCI) and 14 elderly people without memory problems.
Two patients with melanoma that had spread to the liver survived for at least 8.5 and 12 years after resection of the hepatic tumor and treatment with patient-specific immunotherapeutic vaccines.
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases..
Physicians at the Jefferson Hospital for Neuroscience (JHN), the region's only dedicated hospital for neuroscience, are tackling a particularly aggressive brain cancer that even surgery, chemotherapy and radiation often fail to treat with a promising new immunotherapy to attack a patient's tumor with their own cancer cells.
› Verified 4 days ago
Bio-Medical Applications Of Alabama Inc. Location: 1205 Belleville Ave., Brewton, Alabama, 36426 Phone: (251) 867-3650 |
Renal Treatment Centers Southeast, Lp Location: 1023 Douglas Avenue, Brewton, Alabama, 36426 Phone: (251) 867-8509 |
News Archive
For the study, PET scans were performed on the brains of 13 elderly men and women with mild cognitive impairment (MCI) and 14 elderly people without memory problems.
Two patients with melanoma that had spread to the liver survived for at least 8.5 and 12 years after resection of the hepatic tumor and treatment with patient-specific immunotherapeutic vaccines.
A two-year trial of entecavir followed by lamivudine (LAM) in patients with chronic hepatitis B virus (HBV) infection resulted in a virologic rebound rate of 24% and 12% drug-resistance rate. Patients who continued on entecavir therapy throughout the study period had undetectable HBV DNA at the two-year endpoint. Details of this trial are published in the April issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases..
Physicians at the Jefferson Hospital for Neuroscience (JHN), the region's only dedicated hospital for neuroscience, are tackling a particularly aggressive brain cancer that even surgery, chemotherapy and radiation often fail to treat with a promising new immunotherapy to attack a patient's tumor with their own cancer cells.
› Verified 4 days ago